The prospective, open-label, multicentre, non-comparative, observational post-marketing surveillance study evaluating efficacy and tolerability of TRIoptal® (OXcarbazepine) in children and adolescents with newly diagnosed partial seizures or generalized tonic-clonic seizures as monotherapy in routine clinical practice

Novartis India LimitedSandoz House, 5th floorShivsagar EstateDr. Annie Besant RoadIndia1 site in 1 country500 target enrollmentStarted: TBD

Trial Snapshot

Phase: Phase 4
Sponsor
Enrollment: 500
Locations: 1
Primary Endpoint: Seizure Frequency: Reduction is seziure frequency from baseline to end of treatment.

No summary available.

•Male or female children & adolescents between 1 month to 18 years of age (both inclusive) with newly diagnosed epilepsy of the following types:2.Partial seizures (including the seizure subtypes of simple and complex partial seizures, and partial seizures evolving to secondarily generalized seizures)or Generalized tonic clonic seizures
•Patients or their parent/legally-authorized guardian having given written, informed consent and/or assent after the nature of the trial had been fully explained (according to the local legal regulatory requirements).

•1.Age less than 1 month or greater than 18 years;2.Patients with evidence of severe or unstable physical illness or medical condition which would prevent them from participating in the clinical trial;3.Any clinically significant abnormal laboratory findings during screening which remain abnormal upon repeated measurement;4.Known hypersensitivity to Oxcarbazepine or any of the components in the formulation;
•Any psychiatric coexistent illness that may affect the patient?s compliance with study procedures;
•Patients with other indications than partial seizures, or generalized tonic-clonic seizures;
•Parents or Guardians who are not willing to sign the Informed Consent form.
•Females of child bearing potential who are planning to become pregnant or who are pregnant.

Seizure Frequency: Reduction is seziure frequency from baseline to end of treatment.

Time Frame: From baseline to end of study at 24 weeks

Tolerability of the drug: Adverse Events and Serious Adverse Events(From enrollment to end of study at 24 weeks)

Sponsor

Novartis India LimitedSandoz House, 5th floorShivsagar EstateDr. Annie Besant RoadIndia

Loading locations...